Australia’s approval of MDMA and psilocybin for PTSD and depression is premature, say critics
No abstract is available for this record.
Bibliographic context
Topics and keywords
Citation graph
0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.
Indexed papers citing this DOI
Related papers
Australia to prescribe MDMA and psilocybin for PTSD and depression in world firstNature · 2023-06-29The Therapeutic Potential of Psilocybin and 3,4-Methylenedioxymethamphetamine in the Treatment of Depression and Post-Traumatic Stress DisorderDiva portal (Dalarna University Library) · 2019-12-31Attitudes and perceptions of Portuguese mental health professionals on the therapeutic use of psilocybin and methylenedioxymethamphetamine (MDMA).Professional Psychology Research and Practice · 2026-01-31Expectancies for Subjective and Antidepressant Effects in Psilocybin UsersJournal of Humanistic Psychology · 2023-09-21Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant DepressionJournal of Humanistic Psychology · 2017-06-18Effects of LSD and Psilocybin on Heart Rate in Patients Receiving Psychedelic Treatment for Depressive and Anxiety Disorders: A Retrospective Observational StudyPsychology International · 2025-12-18The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysisBMC Psychology · 2026-01-01Psilocybin as a healerConsciousness Spirituality & Transpersonal Psychology · 2022-09-11